Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational...
discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 26, 2024 8:55pm
RE:RE:What's it worth?
you forgot "to infinity and beyond" No one is cashing out because they don't see the future upside, on the contrary they are taking a cap loss now to snag more of the soon to be
...more
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jul 26, 2024 5:40pm
RE:What's it worth?
this is the rocket fuel indeed we won't be on the launch pad forever the pieces are falling into place destiny is all
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Jul 26, 2024 4:51pm
closing in...
closing in on my 10,000 share target Thanks to the seller who dumped hundreds of thousands of shares this morning on good news (as far as I can tell). Maybe they did not foresee the
...more
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 26, 2024 2:01pm
RE:Side effects
It's probably linked to the 14m share day, a control block accumulated there has now served its purpose and can be moved to gain a tax loss.
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Jul 26, 2024 12:11pm
Let's go!!!!
Great news today! On to Phase 1b!!! Let's get it PMN...
(198)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Jul 26, 2024 11:34am
Side effects
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious
...more
(12)
•••
Hafness
X
View Profile
View Bullboard History
Comment by
Hafness
on Jul 26, 2024 11:20am
RE:RE:RE:RE:Positive first results!
I would think so. Good time to buy
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jul 26, 2024 11:07am
RE:RE:RE:Positive first results!
However, would you not think that a positive Ph1a top line and the financing would be good news, enough to move the share price in a positive direction? G1945V
(36)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jul 26, 2024 10:37am
RE:RE:Positive first results!
Since the deal is all about risk mitigation for the largest investors I'm guessing the early action is just account shuffling for tax. How long did really they sit on this deal
...more
(21)
•••
BottomBroker
X
View Profile
View Bullboard History
Post by
BottomBroker
on Jul 26, 2024 9:44am
Now it gets interesting
Let's get PMN310 into some actual AZ patients and see if it really works.
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jul 26, 2024 9:43am
RE:Positive first results!
Can someone explain the drop in the share price this morning? G1945V
(12)
•••
Hafness
X
View Profile
View Bullboard History
Post by
Hafness
on Jul 26, 2024 9:14am
Positive first results!
Beautiful! Love to see this. 120 million in private placement.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 26, 2024 8:35am
New Press Release - ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 26, 2024 8:30am
New Press Release - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approvalFundraise supports development of novel antibody PMN310 for Alzheimer’s Disease patientsProceeds expected to support Company beyond 6...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences